Increased or abnormally regulated cell proliferation plays an important role in carcinogenesis. Bombesin like peptides are growth factors for a number of cell types, including bronchial epithelial cells. A number of studies in animal models have demonstrated that pulmonary carcinogens, including tobacco smoke, can increase the level of bombesin like peptides in the lung. Studies in humans have demonstrated elevated levels of bombesin like peptides in the lower respiratory tract of clinically normal smokers: a subset of whom display levels outside the range found in nonsmokers. Urinary levels of bombesin like peptides appear to identify individuals with elevated lower respiratory bombesin like peptides. There hypotheses will be tested: 1. Elevated levels of bombesin like peptides identify individuals at high risk for the development of lung cancer. 2. Smoking cessation and/or treatment with chemopreventive agents may lower bombesin like peptide levels along with lung cancer risk. 3. The bombesin like peptide found in smokers may be a new member of this peptide family.
Specific aims i nclude: 1. Cross sectional studies of bombesin like peptide levels in lung cancer and controls. 2. Prospective analysis of a cohort of moderate to high risk smokers. 3. Serial analysis of bombesin like peptide levels in smoking cessation and chemoprevention studies. 4. Molecular characterization of bombesin like peptides in urine and bronchoalveolar lavage.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-03S2
Application #
3731451
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Ren, Shengxiang; Zhang, Shucai; Jiang, Tao et al. (2018) Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology 7:e1384108
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543

Showing the most recent 10 out of 435 publications